Barbara Domayne Hayman
Membre du Comité d'Investissement chez Cambridge Enterprise Ltd.
Profil
Barbara Domayne Hayman is currently an Investment Committee member at Cambridge Enterprise Ltd.
and the Chief Business Officer at Autifony Therapeutics Ltd.
She holds a doctorate degree from the University of Oxford.
Postes actifs de Barbara Domayne Hayman
| Sociétés | Poste | Début |
|---|---|---|
Cambridge Enterprise Ltd.
 Cambridge Enterprise Ltd. Investment ManagersFinance Cambridge Enterprise Ltd.(CEL) is a Venture Capital firm, a subsidiary of University of Cambridge founded in 1972. Headquartered in Cambridge. | Membre du Comité d'Investissement | - |
Autifony Therapeutics Ltd.
 Autifony Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Autifony Therapeutics Ltd. discovers and develops new pharmaceutical treatments treat hearing disorders. The firm focuses on the treatment of hearing disorders, including noise-induced hearing loss and tinnitus. The company was founded by Charles H. Large and Giuseppe S. Alvaro in 2011 and is headquartered in London, the United Kingdom. | Corporate Officer/Principal | - |
Formation de Barbara Domayne Hayman
| University of Oxford | Doctorate Degree |
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 2 |
|---|---|
Cambridge Enterprise Ltd.
Cambridge Enterprise Ltd. Investment ManagersFinance Cambridge Enterprise Ltd.(CEL) is a Venture Capital firm, a subsidiary of University of Cambridge founded in 1972. Headquartered in Cambridge. | Finance |
Autifony Therapeutics Ltd.
Autifony Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Autifony Therapeutics Ltd. discovers and develops new pharmaceutical treatments treat hearing disorders. The firm focuses on the treatment of hearing disorders, including noise-induced hearing loss and tinnitus. The company was founded by Charles H. Large and Giuseppe S. Alvaro in 2011 and is headquartered in London, the United Kingdom. | Health Technology |